Enanta Pharmaceuticals, Inc. (ENTA)

Over the past six months, Enanta's stock price has significantly increased by approximately 139.52%. Key events include positive topline results for EDP-323 in a Phase 2a challenge study for RSV, presentations of new clinical data for zelicapavir and EDP-323 at IDWeek™ 2025, an upgrade from Hold to Buy by Jefferies, and JP Morgan initiating coverage with an Overweight recommendation. The company reported its fiscal fourth-quarter and year-ended September 30, 2024, financial results in November 2024.

Demand for Enanta Pharmaceuticals' products can exhibit seasonality, particularly for its RSV-focused pipeline. RSV infections typically show a seasonal resurgence during the colder months, from fall to spring in the Northern Hemisphere, with peak incidence between December and March. Hepatitis B infection seasonality is less consistent. Initiation of biologic therapy for inflammatory conditions like psoriasis has been observed to peak in the spring.

Enanta Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing small molecule drugs for viral infections and immunological diseases. The company's approach is chemistry-driven to develop oral drugs. Its pipeline includes glecaprevir, a protease inhibitor and a key component of AbbVie's MAVYRET®/MAVIRET® for chronic hepatitis C virus (HCV) infection. Current clinical programs focus on respiratory syncytial virus (RSV) with zelicapavir and EDP-323 in Phase 2 clinical development. Enanta also has development programs for SARS-CoV-2 (EDP-235) and Hepatitis B virus (HBV) (EDP-514), and an immunology pipeline targeting inflammatory diseases.

Enanta Pharmaceuticals is headquartered in Watertown, Massachusetts, USA. Its operations are based in the U.S., while its discovered compound glecaprevir is sold worldwide by AbbVie under the tradenames MAVYRET® and MAVIRET®.

Enanta Pharmaceuticals maintains a generally positive brand reputation, particularly among analysts, with a consensus rating of "Moderate Buy". The average one-year price target for Enanta Pharmaceuticals is $20.33, suggesting a potential upside of about 45.9% from its current price. The company's historical success in contributing to the cure of over one million patients with chronic hepatitis C virus infection through its collaboration with AbbVie underpins its reputation. Positive clinical trial results for its RSV candidates and favorable analyst coverage have further bolstered its standing.

Enanta Pharmaceuticals has substantial institutional ownership, with approximately 72.4% of its shares held by institutions. Major institutional owners include Farallon Capital Management Llc, Krensavage Asset Management, LLC, Janus Henderson Group Plc, Vanguard Group Inc, and BlackRock, Inc. Farallon Capital Management Llc held 2,122,262 shares, representing 7.36% ownership, and Krensavage Asset Management, Llc held 2,114,444 shares, representing 7.33% ownership as of September 30, 2025.